You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
USANA Health Sciences, Inc. (USNA) - free report >>
Appian Corporation (APPN) - free report >>
NRx Pharmaceuticals, Inc. (NRXP) - free report >>
Image: Bigstock
New Strong Buy Stocks for December 30th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
CoreCard Corporation (CCRD - Free Report) : This technology solutions and processing services company has seen the Zacks Consensus Estimate for its current year earnings increasing 7% over the last 60 days.
CoreCard Corporation Price and Consensus
CoreCard Corporation price-consensus-chart | CoreCard Corporation Quote
Appian Corporation (APPN - Free Report) : This software company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.
Appian Corporation Price and Consensus
Appian Corporation price-consensus-chart | Appian Corporation Quote
USANA Health Sciences, Inc. (USNA - Free Report) : This nutritional, personal care, and skincare products company has seen the Zacks Consensus Estimate for its next year earnings increasing 12.8% over the last 60 days.
USANA Health Sciences, Inc. Price and Consensus
USANA Health Sciences, Inc. price-consensus-chart | USANA Health Sciences, Inc. Quote
Entrada Therapeutics, Inc. (TRDA - Free Report) : This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 days.
Entrada Therapeutics, Inc. Price and Consensus
Entrada Therapeutics, Inc. price-consensus-chart | Entrada Therapeutics, Inc. Quote
NRx Pharmaceuticals, Inc. (NRXP - Free Report) : This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. Price and Consensus
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.